ROCKVILLE, MD and SHENZHEN, CHINA, August 29, 2024—HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the development of multifunctional multi-targeted therapies for chronic liver and metabolic diseases, announced today that Leigh MacConell, Chief Development Officer will present at the H.C. Wainwright 26th Annual Global Investment Conference. Additionally, the company will participate in investor meetings. This hybrid conference is taking place September 9-11, 2024 in New York City and on-line.

The HighTide presentation will be accessible here starting 07:00 a.m. EDT on September 9, 2024 and will be available for 90 days. 

About HighTide Therapeutics

HighTide Therapeutics, Inc. (2511.HK) is a globally integrated biopharmaceutical company focusing on the discovery and development of first-in-class multifunctional multi-targeted therapies with chronic liver and metabolic diseases with significant unmet medical needs. The company is developing multiple clinical assets, including therapy for metabolic dysfunction-associated steatohepatitis (MASH), type 2 diabetes (T2DM), severe hypertriglyceridemia (SHTG), primary sclerosing cholangitis (PSC). Berberine ursodeoxycholate (HTD1801), the company’s lead drug candidate, received Fast Track designation from the U.S. FDA for both NASH and PSC, as well as Orphan Drug designation for PSC. In China, HTD1801 has been included in the National Major New Drug Innovation Program under the 13th Five-Year Plan for Major Technology Project.

For more information, please visit www.hightidetx.com

Contact: pr@hightidetx.com